ILYANG PHARMACEUTICAL CO.,LTD Logo

ILYANG PHARMACEUTICAL CO.,LTD

Develops & manufactures drugs, vaccines & supplements for oncology & gastroenterology needs.

007570 | KO

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
South Korea
Address:
경기도 용인시 기흥구 하갈로 110, 용인시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Founded in 1946, Ilyang Pharmaceutical is a research-driven company focused on the development and manufacturing of pharmaceutical products. The company's portfolio includes a wide range of prescription drugs, over-the-counter medications, vaccines, and health supplements. It has developed key products in therapeutic areas such as oncology, gastroenterology, and circulatory system disorders. Notable developments include Supect®, a new chemical entity for the treatment of leukemia, and Noltec®, an anti-ulcer agent. Ilyang emphasizes high-quality production through advanced manufacturing facilities and a commitment to innovation in addressing global health needs.

This is a Fraction of the Available Data.

You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for ILYANG PHARMACEUTICAL CO.,LTD and 9,000+ other companies.

Stop analyzing yesterday's news. Start building a real-time advantage.

Request Enterprise API Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-09-11 00:00
Legal Proceedings Report
회계처리기준위반에따른검찰고발등조치
Korean 7.0 KB
2025-09-11 00:00
Legal Proceedings Report
기타시장안내 (상장적격성 실질심사 사유 발생)
Korean 4.9 KB
2025-09-11 00:00
Legal Proceedings Report
[기재정정]기타시장안내 (상장적격성 실질심사 사유 발생)
Korean 8.2 KB
2025-09-10 00:00
Regulatory News Service
매매거래정지및정지해제(풍문등조회공시)
Korean 5.1 KB
2025-09-10 00:00
Legal Proceedings Report
조회공시요구(풍문또는보도)
Korean 3.5 KB
2025-09-05 00:00
Regulatory News Service
[기재정정]단일판매ㆍ공급계약체결
Korean 13.1 KB
2025-08-18 00:00
Transaction in Own Shares
주요사항보고서(자기주식취득신탁계약해지결정)
Korean 27.7 KB
2025-08-18 00:00
Transaction in Own Shares
신탁계약해지결과보고서
Korean 19.8 KB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.6 MB

Automate Your Workflow. Get a real-time feed of all ILYANG PHARMACEUTICAL CO.,LTD filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for ILYANG PHARMACEUTICAL CO.,LTD via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
MYUNGMOON PHARM CO.,LTD Logo
Develops, manufactures, and commercializes prescription & OTC medicines for global markets.
South Korea 017180
Nanexa AB Logo
Develops long-acting injectables using its proprietary nanotechnology for its own pipeline and partners.
Sweden NANEXA
Nanobiotix Logo
Develops a first-in-class radioenhancer to amplify radiotherapy's effect directly within tumors.
France NANO
Nanoform Finland OYJ Logo
Pharma tech firm engineering nanoparticles to enhance drug performance and development.
Finland NANOFH
NanoGroup S.A. Logo
Develops patented nanotechnology for oncology and transplantology diagnostics and therapies.
Poland NNG
NanoRepro AG Logo
Develops and distributes rapid diagnostic self-tests for early disease detection.
Germany NN6
NATAC Logo
Develops sustainable plant extracts for nutraceutical, pharma, food, and animal nutrition industries.
Spain NAT
Biotech R&D of natural ingredients for health and wellness solutions.
South Korea 168330
Naturland Holding PLC Logo
A Hungarian company providing full-scale pharmaceutical manufacturing from R&D to sales.
United Kingdom NATUR
NeoImmuneTech, Inc. Logo
Develops NT-I7, a T cell-amplifying immunotherapy for cancer and infectious diseases.
United States of America 950220

Talk to a Data Expert

Have a question? We'll get back to you promptly.